ストックスクリーナーアプリを入手
153.20
1.75%
-2.60
前日終値:
$155.80
開ける：
$153.42
24時間の取引高:
4.85M
Relative Volume:
0.67
時価総額：
$190.12B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
23.73
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
+2.48%
1か月 パフォーマンス:
+24.85%
6か月 パフォーマンス:
+27.54%
1年 パフォーマンス:
+48.17%
1日の値動き範囲:
$150.82
$155.73
1週間の範囲:
$147.07
$157.29
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
153.20 | 193.35B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,044.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.19 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.20 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.12 | 317.44B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
NVS
Novartis Ag Adr
|
161.57 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat
Varma Mutual Pension Insurance Co Has $22.71 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
LSV Asset Management Has $477.26 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock price target raised to $170 from $155 at Wolfe Research - Investing.com
Illinois Municipal Retirement Fund Buys 10,657 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Caisse Des Depots ET Consignations Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Gilead Sciences: Scotiabank Maintains Outperform, PT $177 Feb 2026 - Meyka
Gilead Sciences (GILD) Net Margin Reset Challenges Slower Growth Narratives In FY 2025 Results - simplywall.st
Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire Inc.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy? - Yahoo Finance
Gilead Sciences Earnings Call: HIV Strength, New Catalysts - TipRanks
Gilead Accuses Cipla of Sidestepping Earlier Descovy Patent Deal - Bloomberg Law News
Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Dividend Increase$0.82 Per Share - MarketBeat
Key facts: Gilead Q4 profit hits $2.18B; signs MoU with UAE Health - TradingView
Morgan Stanley Sees Gilead Gaining Ground In HIV And Oncology - Finimize
TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating - marketscreener.com
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026 - TipRanks
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says - marketscreener.com
‘Pieces are coming together’ amid Gilead's Yeztugo launch: exec - Fierce Pharma
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales - Finviz
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Gilead's Long HIV Patent Life and Emerging Oncology Portfolio Support a Wide Moat - Morningstar
Oppenheimer Adjusts PT on Gilead Sciences to $165 From $128, Maintains Outperform Rating - marketscreener.com
Truist Securities raises Gilead Sciences stock price target to $152 - Investing.com India
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High on Earnings Beat - MarketBeat
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes - Schaeffer's Investment Research
Bernstein raises Gilead Sciences stock price target to $160 on growth outlook - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital By Investing.com - Investing.com India
Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
GILD: Scotiabank Raises Gilead Sciences Price Target Amidst Sect - GuruFocus
Gilead Sciences stock price target raised to $162 from $154 at BofA - Investing.com
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $177.00 - MarketBeat
Cantor Fitzgerald Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $155.00 - MarketBeat
Gilead Sciences signs MoU with Ministry of Health and Prevention - ZAWYA
Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities - StreetInsider
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $177 - 富途牛牛
Gilead Sciences (GILD) Q4 2025 adj. earnings decline, despite higher revenues - AlphaStreet News
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript - Insider Monkey
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority - BioSpace
Rhumbline Advisers Sells 15,602 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Needham raises Gilead Sciences stock price target to $170 on strong HIV sales - Investing.com India
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO |
Feb 05 '26 |
Sale |
150.00 |
115,640 |
17,346,000 |
613,912 |
0.59%
0.31%
大文字化:
|
ボリューム (24 時間):